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ABSTRACT: Immunotoxins are proteins containing a cell-targeting element linked to a
toxin that are under investigation for next-generation cancer treatment. However, these
agents are diﬃcult to synthesize, chemically heterogeneous, expensive, and show toxicity
toward healthy cells. In this work, we describe the synthesis and characterization of a new
type of immunotoxin that showed exquisite selectivity toward targeted cells. In our con-
struct, targeting molecules were covalently attached or genetically fused to oligomeric pore-
forming toxins. The activity of the immunotoxin was then caged by fusing a soluble protein
to the transmembrane domain and activated via cleavage with furin, which is a protease that
is overexpressed in many cancer cells. During the several coupling steps, directed evolution
allowed the eﬃcient synthesis of the molecules in E. coli cells, as well as selection for further speciﬁcity toward targeted cells.
The ﬁnal construct showed no oﬀ-target activity, while acquiring an additional degree of speciﬁcity toward the targeted cells
upon activation. The pore-forming toxins described here do not require internalization to operate, while the many protomeric
subunits can be individually modiﬁed to reﬁne target speciﬁcity.
■ INTRODUCTION
Protein-based drugs have become increasingly important in the
pharmaceutical industry. In the period from 2011 to 2016, the
FDA approved 62 proteins as drugs,1 most of which contain
monoclonal antibodies (mAb). These agents recognize molec-
ular targets on cancer cell surfaces, blocking their biological
function, or, most often, marking the cells for the body’s
immune system.2 An advantage of this approach is that drugs
can be developed to recognize speciﬁcally a complex biological
signature in malignant cells. However, mAbs are complex
molecules that cannot be synthesized chemically and are
manufactured in living organisms.3 Furthermore, they often
require complex post-translational modiﬁcations that can only
be introduced when heterologous expression systems are
used.4 In addition, since the products are synthesized by cells
or organisms, their chemical modiﬁcation is not straightforward,
and complex puriﬁcation processes are involved.5,6 Finally,
because their large size (up to 150 kDa), they have limited
tumor penetration,7 and they are often recognized by the host
immune system.8
In next-generation targeted cancer therapy,9 mAbs were, e.g.,
conjugated to a drug (antibody-drug conjugates),1,10,11 to a
toxin (immunotoxin or IT),12,13 to a cytokine,14 or to a radio-
active particle.15 In such constructs, the antibody recognizes a
speciﬁc cell target, which allows the deadly cargo to be deliv-
ered to the diseased tissue. In immunotoxins, mAbs or growth
factors are either chemically or genetically fused to a potent
protein toxin, which inhibit protein synthesis, such as diph-
theria toxin16 or pseudomonas exotoxin A.17 These are very
eﬃcient toxins, because they act catalytically on their cytosolic
targets, hence, at very low concentrations. However, ITs must
be internalized into the cell and not every target has a suﬃcient
internalization rate, allowing suﬃcient accumulation of toxo-
phore to eﬀectively kill cancer cells.18−20 Hence, highly potent
payload drugs must be used frequently, which, in turn, can
produce life-threatening toxicities.21 In fact, the high potency
of the payload requires a highly selective expression of mem-
brane targets in cancer cells compared to healthy cells,22 and
the number of suitable targets may be limited to just a few
dozen.23
Alternative hybrid molecules might be built from membrane-
acting toxins, which assemble into unregulated oligomeric pores
in the membrane of targeted cells. Diﬀerent hemolytic toxins
from sea anemones, bacteria, or humans24−26 have been used
to target diﬀerent cell lines, including immature T lympho-
cytes,27 leukemic cells,26 breast cancer cells,28 lung cancer
cells,29 or colon cancer cells.30 Since hundreds of pores might be
necessary to obtain a cytotoxic eﬀect,31 pore-forming toxins are
much less potent than intracellular toxins commonly used in
ITs. However, toxicity may be complemented or regulated by
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using other drugs, which are preferably internalized into the
cells permeabilized by the pore-forming toxin.32 In addition,
each monomer of the pore could be fused to diﬀerent targeting
elements, which, in turn, should bring a higher level of control
of the targetability of the drug. However, the main limitation of
most pore-forming immunotoxins is their basal toxicity toward
most cells, including red blood cells, which, in turn, prevents
their pharmacologic use.
In nature, many toxins are synthesized as protoxin and
activated by proteolytic removal of a polypeptide segment at
either terminus. Cancer cells often overexpress speciﬁc tumor-
associated proteases, which are important for the invasion and
metastasis of cancer cells.33,34 In one approach, to reduce the
toxicity toward healthy cells, immunotoxins have been pre-
pared to speciﬁcally cleave the linker between the targeting
moiety and the payload by intracellular cancer-associated pro-
teases, hence activating the toxin in situ.35,36 Pore-forming
toxins have also been inactivated by genetic fusion with a
polypeptide trigger and then proteolytically activated by
cancer-associated proteases.37,38
In this work, we describe the preparation of pore-forming
immunotoxins consisting of a chemical or protein-based
targeting element, a pore-forming toxin, and a protease trigger
(see Figure 1). Crucially, each fusion step is optimized by
directed evolution, which allowed the toxicity to be tuned
toward the target cells, as well as eﬃcient synthesis of the
protein complexes in E. coli cells. We show a construct that
recognizes a molecular target on cancer cells and is selectively
activated by a cancer-associated protease, while displaying no
oﬀ-target activity on other cells.
■ RESULTS AND DISCUSSION
Immunotoxin Preparation by Targeted Chemical
Modiﬁcation. Cytolysin A (ClyA) is a protein toxin syn-
thesized as soluble 34 kDa monomeric protein, which assem-
bles into a dodecameric pore, causing the lysis of cell mem-
branes rich in cholesterol.39 In our ﬁrst eﬀort to prepare an
immunotoxin, we conjugated folate to a cysteine residue intro-
duced at position 272 in a previously engineered cysteine-less
ClyA (ClyA-AS) from Salmonella typhi.40 Folate was covalently
attached to ClyA-AS-S272C monomers via a PEG-5K linker
bearing a maleimide moiety (see Figure 2A). SDS-PAGE
revealed that ∼50% of the ClyA-AS-S272C was conjugated
(see Figure 2B). The construct was puriﬁed by size exclusion
chromatography (SEC) and tested for cytotoxic activity on KB
cells overexpressing folate receptors (FR). A MTT assay,
which assesses the cell metabolism by measuring the mito-
chondrial potential, revealed that conjugation to folate increased
toxicity toward FR+ cells by ∼2-fold [IC50(ClyA-folate) = 5.45 nM
vs IC50(ClyA) = 13.5 nM] (see Figure 2C). In order to conﬁrm
that ClyA-folate induces preferential cell lysis, we added 10 nM of
ClyA-folate to FR+ and FR− cells containing culture medium
with a standard folate concentration (0.002 mM), and we
assessed the integrity of the cell membrane using a propidium
iodide assay. Under these conditions, we found that ClyA-
folate causes increased cell death in FR+ cells but not in FR−
cells (see Figure 2D). This diﬀerence is abolished when
folate concentration in the medium is increased 250-fold (see
Figure 2D). This suggests that cell death mediated by ClyA-
folate is receptor-mediated. Thus, conjugation of ClyA with
folate increases its speciﬁcity to FR+ cells, making this a possi-
ble candidate for a targeted therapy approach against FR-
overexpressing tumors.
A Genetically Encoded Immunotoxin. In a second
approach, the anti-EGFR nanobody 7d1241,42 was genetically
attached to the C-terminus of ClyA-AS via a 16 amino acid
long linker (see Figure 2E). EGFR overexpression in cells is
associated with diﬀerent cancer types and is an indication of
especially aggressive breast cancer.43,44 The ClyA-AS-nanobody
construct (ClyA-Nb) was overexpressed in E. coli cells and
puriﬁed by Ni-NTA aﬃnity chromatography. Conjugation to
the nanobody preserved hemolytic activity of ClyA toward
sheep red blood cells (see Figure 3E, as well as Figure S2D in
the Supporting Information). To test whether nanobody
attachment improved toxicity toward EGFR-overexpressing
cells, we measured the mitochondrial activity of A431 epider-
moid carcinoma cells, overexpressing EGFR,45 at increasing
concentration of immunotoxin. The cell viability experiments
showed a 2-fold reduced IC50 of ClyA-Nb [IC50(ClyA-Nb) =
7.2 ± 1.1 nM], compared to ClyA-AS [IC50(ClyA) = 17.1 ±
2.9 nM] (see Figure 2F). Incubation with EGF abolished this
diﬀerence (see Figure 2G, as well as Figures S1A, S1B,
and S3A in the Supporting Information). Thus, as observed for
ClyA-folate conjugation, the attachment of the targeting unit
increased toxicity to the target cells by 2-fold, making ClyA-Nb
a possible candidate for a targeted therapy approach against
EGFR-overexpressing tumors.
Protein Engineering Allows Eﬃcient Synthesis in
E. coli and Improves Targetability toward Cancer Cells.
To increase speciﬁcity of ClyA toward the membranes of target
Figure 1. Modular nanopore immunotoxins. (A) Schematic
representation of diﬀerent modules used to build up a pore-forming
immunotoxin with caged activity. The central point is the toxin.
In this study, we used the membrane-acting toxins ClyA and FraC.
The C-terminus of the toxin was conjugated to diﬀerent targeting
molecules, including folate and an anti-EGFR nanobody, to direct the
toxin to cancer cells. For site-speciﬁc activation of the toxin, DHFR
was fused to the N-terminus of the toxin via a cancer protease
sensitive linker. Activation of the toxin by proteolysis is necessary to
enable pore formation and, thus, cell killing activity. (B) Schematic
representation of the pore formation of the designed protein drug.
Soluble toxin is recruited to the host membrane by interactions of the
targeting module and the corresponding receptor. Subsequent
proteolytic cleavage at the speciﬁc protease site is necessary for
activation of the toxin. Finally, the toxin can insert into the
membrane. Pore formation changes membrane permeability,
ultimately leading to cell death.
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cancer cells, we performed random mutagenesis using degen-
erate primers targeting isoleucine 5 and phenylalanine 6 in
ClyA-Nb (see Figure 3A). The two residues are hydrophobic
and are located just before the transmembrane region of ClyA.
Thus, we hypothesized they are important for membrane
binding. An initial negative screening on red blood cells was
performed, where toxins which showed slower hemolysis rates
than ClyA-Nb were selected. This step was intended to reduce
the aﬃnity of the toxin for nontarget cell membrane. Moderate
active variants were then puriﬁed by Ni-NTA aﬃnity
chromatography and tested for expression and purity by blue
native polyacrylamide gel electrophoresis (BN-PAGE; see
Figure 3C, as well as Figure S2A in the Supporting Infor-
mation). Variants, which were highly expressed and showed no
preoligomerization (i.e., they do not oligomerize in the absence
of membranes or surfactants) were then selected and tested on
A431 cells. Among the variants tested, SE-ClyA-Nb could be
puriﬁed with reasonably high yields (∼1 mg from 300 mL
culture), showed low tendency to preoligomerize, and showed
a 3-fold slower hemolytic activity, compared to ClyA-AS and
ClyA-Nb [t50(ClyA-AS) = 12 min, t50(ClyA-Nb) = 14 min, and
t50(SE-ClyA-Nb) = 48 min for 1 μg toxin] (see Figure S2D in
the Supporting Information). Crucially, the toxicity on A431
cells improved 2-fold more, compared to ClyA-Nb [IC50(SE-
ClyA-Nb) = 4.1 ± 0.5 nM] (see Figure 3F). In the presence of
15 nM, EGF the toxicity reduced 4-fold [IC50(SE-ClyA-Nb,
EGF) = 16.0 ± 0.7 nM] (see Figure 3G, as well as Figures S3B
and S3C in the Supporting Information) to the level observed
for ClyA [IC50(ClyA, EGF) = 18.5 ± 3.1 nM] (see Figure 3H),
indicating that the additional toxicity of SE-ClyA-Nb is due to
the speciﬁc interaction of the nanobody with the cancer cell
receptors.
Toxins Can Be Exchanged. The cytotoxic eﬃciency of
ClyA toxins is dependent on the membrane composition of the
targeted cell line. Thus, to reﬁne and generalize our approach,
we exchanged the ClyA nanopore toxin for the actinoporin
Fragaceatoxin C (FraC). Similarly to ClyA, FraC is a pore-
forming toxin that is expressed as a water-soluble monomer
and self-assembles into (octameric) transmembrane pores.
However, the N-terminal membrane spanning region of FraC
interacts tightly with three sphingomyelin molecules per
monomer (see Figure S4A in the Supporting Information).
Thus, FraC requires sphingomyelin to cause cell damage.46
The anti-EGFR nanobody containing the 18-amino acid linker
used to prepare ClyA-Nb was fused to the C-terminus of S-FraC
to prepare S-FraC-Nb. S-FraC carries the mutation W112S,
compared to wild-type (WT) FraC that we found increased its
expression in E. coli cells. S-FraC-Nb could be puriﬁed at high
yield in E. coli cells and exhibited hemolytic activity that was
similar to that of S-FraC (see Figure S4C in the Supporting
Figure 2. ClyA targeting cancer cells. (A) Schematic representation of ClyA (blue, PDB: 2WCD) conjugated to folate. Folate was covalently
attached to ClyA-AS-S272C via a disulﬁde bond and a PEG linker. (B) ClyA folate conjugation examined by 12% SDS-PAGE electrophoresis.
Lanes 1 and 2: ClyA-AS-S272C modiﬁed with folate-5k PEG-maleimide showing ∼50% modiﬁcation. The arrow indicates modiﬁed ClyA-folate,
the band below the arrow is unmodiﬁed ClyA, while additional bands above the arrow most likely represent additional incorporations of PEG-folate
molecules reacting to lysine residues in ClyA-AS. Lanes 3 and 4: ClyA-AS-S272C prior modiﬁcation. (C) Comparison of the IC50 values of ClyA
and fol-ClyA in FR-positive KB cells. (D) Comparison of cell death of FR-positive cells (KB) and FR-negative cells (A549) by 10 nM Fol-ClyA, in
a standard medium (containing 0.002 mM of folate) and in a medium supplemented with 250-fold higher folate concentration (0.5 mM).
(E) Schematic representation of ClyA conjugated to nanobody at the C-terminus. ClyA is shown in blue the anti-EGFR nanobody 7D12 is shown
in red (PDB: 4KRL). (F) Representative dose−response curves of ClyA-AS and ClyA-Nb in the absence of EGF. Conjugation to the anti-EGFR
nanobody increases toxicity toward EGFR overexpressing A431 cells. (G) Comparison of the IC50 values of ClyA and ClyA-Nb, in the presence and
absence of EGF.
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Information), indicating that the protein fusion did not impair
protein activity. As observed for ClyA, the fusion to the nano-
body increases the toxicity of S-FraC by 2-fold toward EGFR-
overexpressing cells [IC50(S-FraC) = 135.5 ± 22.7 nM, vs
IC50(S-FraC-Nb) = 63.9 ± 16.4 nM] (see Figure S4D in the
Supporting Information). Predictably, 15 nM of EGF reduced
the toxicity of S-FraC-Nb [IC50(S-FraC-Nb, EGF) = 197.9 ±
15.5 nM], but showed no eﬀect on S-FraC [IC50(S-FraC,
EGF) = 138.5 ± 28.7 nM (see Figures S4E, S4F, and S4G in
the Supporting Information)].
A Triggered Toxin Improved by Directed Evolution.
Although directed evolution could increase the aﬃnity of
SE-ClyA-Nb for A431 cells while decreasing the toxicity toward
red blood cells, the latter could not be completely abolished.
Many tumor cells secrete proteases such as furin,34,47,48 uroki-
nase plasminogen activator,49 or cathepsin B,50 which, in turn,
activates other proteases, eventually promoting tumor meta-
stasis by helping tumor cells digest the extracellular matrix and
penetrate the basal lamina. Therefore, we planned to design an
immunotoxin that is activated by furin. To silence the toxicity
of ClyA, we fused dihydrofolate reductase (DHFR, 19 kDa) to
the N-terminus of the ClyA-Nb and FraC-Nb toxins via an
18-amino-acid-long linker containing a furin cleavage site (see
Figure 4A, as well as Figure S5A in the Supporting Infor-
mation). DHFR was selected because it is a relatively small
protein that shows high water solubility, is expressed well in
E. coli cells, and is nontoxic to human cells. The digestion of
the constructs by furin will then remove DHFR, thereby
activating the toxin. Surprisingly, however, DHFR-SE-ClyA
showed similar hemolytic activity as SE-ClyA-Nb, indicating
that DHFR-SE-ClyA-Nb can oligomerize on membranes, despite
the large protein on the transmembrane helix (Figure S5C in the
Supporting Information). By contrast, the DHFR-FraC construct
was much less hemolytic active. However, the construct
suﬀered from a small background activity on red blood cells,
and it could not be puriﬁed at high concentrations, because of
aggregation.
To improve the E. coli synthesis of the DHFR-FraC con-
struct, we performed three rounds of random mutagenesis on
the entire construct. Libraries were generated by error-prone
PCR and screened for hemolytic activity in the presence and
absence of protease. Variants were selected that showed low or
no background activity but were hemolytic active after proteo-
lytic cleavage. The best three variants from the third round
were puriﬁed by Ni-NTA aﬃnity chromatography and com-
pared using hemolytic activity. MD-DHFR-FraC (displaying
the T50M mutation on the DHFR sequence and the N325D
mutation in the FraC sequence), C-DHFR-FraC (R312C at the
interface of FraC protomers), and HC-DHFR-FraC (R102H in
the active site of DHFR and R312C at the interface of FraC
protomers) did not induce red blood cell lysis after the addi-
tion of 10 μg of the puriﬁed proteins (see Figure 4B, as well as
Figure S6A in the Supporting Information). However, upon
incubation with furin (3 h, 37 °C), all mutants lysed red blood
cells within minutes [t50(C-DHFR-FraC) = 4.8 min, t50(HC-
DHFR-FraC) = 5 min, and t50(MD-DHFR-FraC) = 2.8 min
Figure 3. Directed evolution of ClyA-Nb. (A) Schematic representation of ClyA conjugated to nanobody. The amino acids at the N-terminus are
not observed in the crystal structure of ClyA, suggesting that they do not have a well-deﬁned secondary structure. Amino acids 5 and 6, which were
mutated to improve toxin properties, are shown in red. (B) Hemolytic activity of a part of the ClyA-Nb library. Hemolysis rates are presented as a
percentage of ClyA-Nb activity. (C) Part of the ClyA-Nb library analyzed by a 4%−20% blue-native PAGE.40 Lane 1, protein ladder; lane 2, ClyA-Nb;
lane 3, ClyA-Nb with 0.2% SDS; lane 4, SE-ClyA-Nb; lane 5, SE-ClyA-Nb with 0.2% SDS; lane 6, FR-ClyA-Nb; lane 7, FR-ClyA-Nb with 0.2% SDS;
lane 8, QR-ClyA-Nb; lane 9, QR-ClyA-Nb with 0.2% SDS; lane 10, GG-ClyA-Nb; and lane 11, GG-ClyA-Nb with 0.2% SDS. (D) ClyA-nanobody
fusion puriﬁcation examined by 12% SDS-PAGE. Lane 1, protein ladder; lane 2, ClyA; lane 3, ClyA-Nb; and lane 4, SE-ClyA-Nb.
(E) Comparison of the hemolysis percentage of ClyA and ClyA-Nb constructs. Fusion of ClyA to the Nb reduces hemolytic activity and the
mutation I5S and F6E of ClyA reduces activity even further. (F) Toxicity of ClyA constructs toward EGFR overexpressing A431 cells, showing that
both the nanobody and the additional mutation at the N-terminus improve toxicity toward the cells. (G) Toxicity of SE-ClyA-Nb in the presence
and absence of 15 nM EGF, showing that the eﬀect of the increased toxicity of SE-ClyA-Nb is due to the nanobody. (H) Comparison of the IC50
values of ClyA, ClyA-Nb, and SE-ClyA-Nb in the presence and absence of EGF, showing the high speciﬁcity of the SE-ClyA-Nb construct.
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for 10 μg toxin] (see Figure 4B). MD-DHFR-FraC was selected
for further cytotoxic characterization on A431 cells. The
addition of up to 600 nM DHFR-FraC caused no cell death,
while an equal concentration of proteolyzed MD-DHFR-FraC
showed cytotoxicity comparable to S-FraC [IC50(cut FraC) =
98.9 ± 11.9 nM] (see Figure 4C).
In order to test whether a DHFR-FraC construct can be
activated by a cell-secreted protease, the MD-DHFR-FraC was
tested on Calu-6 cells, which is a cell line expressing the prote-
ase furin,51,52 the latter is a protease that is overexpressed by
many cancer cells.34,51 Rewardingly, MD-DHFR-FraC showed
cytotoxicity on Calu-6 cells [IC50 = 212.0 ± 35.4 nM] that was
comparable to the preproteolyzed MD-DHFR-FraC [IC50 =
142.5 ± 30.5 nM] (see Figure 4D). In contrast, when up to
820 nM of a caged immunotoxin containing a TEV (DHFR-
(TEV)-FraC) rather than a furin cleavage site was used, no
cytotoxic activity was observed (see Figure 4E), indicating that
the activation of FraC by Calu-6 cells was induced by furin and
not by other nonspeciﬁc proteases.
A Triggered Immunotoxin. In the last step, the nanobody
was genetically fused to the C-terminus of evolved MD-DHFR-
FraC (see Figure 5A). Although the size of the protein increased
to 56 kDa, no additional directed evolution was required, as the
construct successfully expressed well in E. coli cells (∼1 mg from
300 mL culture) and could be eﬃciently puriﬁed in one-step by
Ni-NTA aﬃnity chromatography (see Figure 5B). The full
construct (DHFR-FraC-Nb) exhibited no hemolytic activity,
while incubation with furin induced red blood cell lysis within a
few minutes [t50(DHFR-FraC-Nb) = 4.6 min for 10 μg toxin]
(see Figure 5C). As expected, DHFR-FraC-Nb was not cyto-
toxic toward A431 cells (24 h incubation) (see Figure 5D), but
caused cell death after incubation with furin [IC50 = 146 ±
18.5 nM] (see Figure S7B in the Supporting Information).
Cytotoxicity was reduced when EGF was added to the growth
medium [IC50 = 283.9 ± 15.1 nM] (see Figure S7C in the
Supporting Information), conﬁrming that the interaction with
the cell membrane receptor increased the immunotoxin
activity. In situ activation of DHFR-FraC-Nb was tested,
using the furin-expressing cell line Calu-6.51,52 As expected,
DHFR-FraC-Nb, which was not active on A431 cells, induced
cell death toward Calu-6 cells [IC50 = 95.2 ± 14.4 nM] (see
Figure 5D, as well as Figures S7B and S7D in the Supporting
Information). The addition of 15 nM EGF reduced the toxicity
of DHFR-FraC-Nb by almost 2-fold [IC50 = 148.2 ± 3.6 nM]
(see Figures S7C and S7E in the Supporting Information).
Most likely, the eﬀect of the nanobody on Calu-6 cells is less
pronounced because this cell line expresses less EGFR than
A431 cells.53
Figure 4. Caging FraC toxin. (A) Schematic representation of FraC conjugated to DHFR. FraC (purple, PDB: 4TSY) fused N-terminal to DHFR
(green, PDB: 1RH3) by an 18-amino-acid-long linker, including a protease cleavage site for furin. (B) Comparison of the hemolytic activity of
diﬀerent DHFR-FraC mutants resulted from directed evolution. Fusion of FraC to DHFR deactivates the toxin and therefore no hemolysis of red
blood cells can be observed. Activation with the protease furin regains hemolytic activity of all mutants. (C) Representative dose−response curves
of MD-DHFR-FraC and proteolyzed MD-DHFR-FraC on A431 cells. Therefore, conjugation to DHFR deactivates the toxin, and no cell killing is
observed for MD-DHFR-FraC. Proteolysis with furin triggers pore formation of the toxin and recovers toxicity toward A431 cells.
(D) Representative dose−response curves of MD-DHFR-FraC (DHFR-(furin)-FraC) and proteolyzed MD-DHFR-FraC on Calu-6 cells. Calu-6
cells produce furin, which activates MD-DHFR-FraC, resulting in cell killing. (E) Representative dose−response curves of DHFR-(TEV)-FraC and
proteolyzed DHFR-(TEV)-FraC on Calu-6 cells. Conjugation to DHFR deactivates the toxin and Calu-6 cells do not express TEV proteases;
therefore, no cell killing is observed for DHFR-(TEV)-FraC. Proteolysis with TEV triggers pore formation of the toxin and recovers toxicity toward
Calu-6 cells.
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■ DISCUSSION
Since the introduction of the ﬁrst recombinant protein thera-
peutic, human insulin, 35 years ago, proteins have long
remained a rarely used subset of medical treatments. In recent
years, protein therapeutics have increased dramatically in
number and frequency of use, and they now have a signiﬁcant
role in almost every ﬁeld of medicine, despite this role is still
only in its infancy. In this work, we describe a method that uses
directed evolution to prepare protein-based therapeutic agents
consisting of a membrane-targeting element covalently linked
to a caged toxin.
We tested ClyA from Salmonella typhi and FraC from Actinia
f ragacea pore-forming toxins as cytotoxic elements. Both toxins
are expressed as soluble monomers that form oligomeric pores
into lipid membranes. In order to direct protein toxicity toward
selected cells, we explored two approaches. A small molecule
folate was chemically attached to ClyA via a 5 kDa PEG linker.
The latter was used to mediate the interaction distance with
the receptor and to facilitate the puriﬁcation of the conjugate.
This approach is fast and might allow the screening of
hundreds of molecules. However, the bioorthogonal chemical
linkages can be instable, and they can produce low reaction
yields that might result in heterogeneous samples. Thus, we
tested a second approach, where the variable antibody domain
of a single-domain camelid antibodies, called nanobodies
(Nb), conjugated to the C-terminus of the toxin. Nanobodies
are small and stable,54 penetrate tissues eﬃciently,55 show low
immunogenicity,56 and can be easily produced in bacteria. For
both approaches, we found that ClyA and FraC toxins conju-
gated to the targeting unit induced a 2-fold increase in IC50
toward cancer cell lines overexpressing the cognate receptor.
In order to improve the soluble expression of the immuno-
toxin, increase target aﬃnity, and reduce the toxicity toward
blood cells, we resorted to a directed evolution experiment in
which the hydrophobic residues at the N-terminus of the ClyA
toxin were randomized. The rationale was that a reduced
aﬃnity of the immunotoxin for nontargeted membranes would
be compensated by the nanobody-mediated binding to a spe-
ciﬁc membrane target, leading to a greater diﬀerence in toxicity
between cell types. Using this approach, we identiﬁed pore-
forming immunotoxins with an additional 2-fold-increased IC50
toward cells expressing EGFR and a 3-fold-reduced oﬀ-target
hemolytic activity. Simultaneously, the production yield in
E. coli cells was more eﬃcient.
In the ﬁnal step, we sought to completely suppress oﬀ-target
activity. In nature, many toxins are synthesized as protoxins that
are proteolytically activated extracellularly. Borrowing from
nature, we introduced a polypeptidic segment at the transmem-
brane N-terminus of FraC and ClyA to cap the activity of the
nanopore toxins. The conjugate was preceded by a cleaving
sequence for furin, which is a cancer-associated protease
involved in degrading the extracellular matrix in tumor forma-
tion and metastasis.57 We found that ClyA was fully active on
red blood cells,58 while the toxicity of FraC was reduced but
not completely abolished. Gladly, the toxicity of the caged
FraC-Nb toxin could be suppressed by three rounds of
Figure 5. A caged pore-forming immunotoxin. (A) Schematic representation of FraC conjugated to DHFR and nanobody. FraC is shown in purple,
DHFR is shown in green, and the C-terminal of anti-EGFR nanobody 7D12 is shown in red. (B) 12% SDS-PAGE to examine DHFR-FraC-
nanobody fusion and its proteolysis. Lane 1, protein ladder; lane 2, DHFR-FraC-Nb; and lane 3, DHFR-FraC-Nb proteolyzed by furin
(1:100 ratio). Only ∼50% of DHFR-FraC-Nb was proteolytically activated. The arrows indicate the proteins of interest, while additional bands
most likely correspond to partial proteolytic products or impurity in the commercial furin sample. (C) Comparison of the hemolytic activity of
DHFR-FraC-Nb and proteolyzed DHFR-FraC-Nb. Only proteolyzed DHFR-FraC-Nb is active. (D) Representative dose−response curves of
DHFR-FraC-Nb toward A431 cells or Calu-6 cells, showing that DHFR-(furin)-FraC-Nb is only active on Calu-6 cells, which is the only cell line
expressing furin necessary for activation.
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directed evolution, allowing one to identify a construct that
was completely inactive toward cellular membranes but fully
active upon in situ protease activation by a cancer cell line
overexpressing furin.
This work describes a method that uses a directed evolution
approach to prepare pore-forming immunotoxins with caged
activity. Our design contains three separate elements that can
be easily exchanged: a water-soluble pore-forming toxin that
oligomerizes on lipid membranes, a membrane targeting unit,
and protein trigger for in situ activation. The targeting element
and the protein trigger allows a two-degree control of the toxin
activity. The pore-forming ability of the immunotoxin may
oﬀer advantages, compared to conventional toxins. The activity
can be easily assayed on red blood cells, which, in turn, allows the
use of random mutagenesis approaches to improve the synthesis
of the proteins in E. coli cells and to ﬁne-tune the properties of
the protein conjugate. In addition, the oligomeric nature of the
assembled cytotoxic pores will allow conjugating the protein drug
with multiple membrane targeting motives, which will allow
further ﬁne-tuning of the cytotoxicity toward targeted cells.
■ METHODS
Hemolytic Activity Assay. Deﬁbrinated sheep blood (Thermo-
Fisher Scientiﬁc) was washed with 150 mM NaCl, 15 mM Tris.HCl
(pH 7.5) until the supernatant was clear. The erythrocytes were then
resuspended with the same buﬀer to ∼1% concentration (OD650 =
0.6−0.8). The suspension (120 μL) was then mixed with the
solutions containing immunotoxin. Hemolytic activity was measured
by monitoring the decrease in OD650 using the MultiskanTM GO
Microplate spectrophotometer (ThermoFisher Scientiﬁc). The hemol-
ysis rate was calculated as the inverse of the time elapsed until a 50%
decrease in turbidity was attained. To determine hemolytic activity of
caged FraC, toxin was mixed with the appropriate protease and
incubated for 5 min before application to the erythrocyte solutions.
Cytotoxicity Assay. Cell viability after the addition of immuno-
toxin was assessed with the WST-8 cell proliferation assay. First,
20 000 cells were seeded per well in a 96-well plate in the corre-
sponding medium and incubated for 24 h. Cells were then treated in
triplicate with varying concentrations of immunotoxins, toxins,
epidermal growth factor and folate. After 24 or 48 h, 5 μL of the
CCK-8 solution was added per well, and the plates were incubated for
2 h under standard conditions. Lastly, the absorption was measured at
450 nm in a MultiskanTM GO Microplate spectrophotometer. IC50
values were calculated by using sigmoidal ﬁtting with Origin
(OriginLab, Northampton, MA). Cell viability of reference wells
with untreated cells was set to 100%.
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Yla-̈Herttuala, S. (2009) Challenges in monoclonal antibody-based
therapies. Ann. Med. 41, 322.
(4) Bandaranayake, A. D., and Almo, S. C. (2014) Recent advances
in mammalian protein production. FEBS Lett. 588, 253−260.
(5) Dingermann, T. (2008) Recombinant therapeutic proteins:
Production platforms and challenges. Biotechnol. J. 3, 90−97.
(6) Liu, H. F., Ma, J., Winter, C., and Bayer, R. (2010) Recovery and
purification process development for monoclonal antibody produc-
tion. MAbs 2, 480−99.
(7) Minchinton, A. I., and Tannock, I. F. (2006) Drug penetration in
solid tumours. Nat. Rev. Cancer 6, 583.
(8) Rosenberg, A. S., and Sauna, Z. E. (2018) Immunogenicity
assessment during the development of protein therapeutics. J. Pharm.
Pharmacol. 70, 584−594.
(9) Baudino, T. A. (2015) Targeted Cancer Therapy: The Next
Generation of Cancer Treatment. Curr. Drug Discovery Technol. 12,
3−20.
(10) Thomas, A., Teicher, B. A., and Hassan, R. (2016) Antibody−
drug conjugates for cancer therapy. Lancet Oncol. 17, e254−e262.
(11) Lambert, J. M., and Berkenblit, A. (2018) Antibody-Drug
Conjugates for Cancer Treatment. Annu. Rev. Med. 69, 191−207.
(12) Pastan, I., Hassan, R., Fitzgerald, D. J., and Kreitman, R. J.
(2006) Immunotoxin therapy of cancer. Nat. Rev. Cancer 6, 559−65.
(13) Alewine, C., Hassan, R., and Pastan, I. (2015) Advances in
anticancer immunotoxin therapy. Oncologist 20, 176−85.
(14) Pasche, N., and Neri, D. (2012) June) Immunocytokines: A
novel class of potent armed antibodies. Drug Discovery Today 17, 583.
(15) Kitson, S. L., Cuccurullo, V., Moody, T. S., and Mansi, L.
(2013) Radionuclide antibody-conjugates, a targeted therapy towards
cancer. Curr. Radiopharm. 6, 57−71.
(16) Williams, D. P., Parker, K., Bacha, P., Bishai, W., Borowski, M.,
Genbauffe, F., Strom, T. B., and Murphy, J. R. (1987) Diphtheria
toxin receptor binding domain substitution with interleukin-2: genetic
construction and properties of a diphtheria toxin-related interleukin-2
fusion protein. Protein Eng., Des. Sel. 1, 493−498.
(17) Mansfield, E., Amlot, P., Pastan, I., and FitzGerald, D. J. (1997)
Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity
for CD22-bearing cells and tumors. Blood 90, 2020−2026.
(18) Du, X., Beers, R., FitzGerald, D. J., and Pastan, I. (2008)
Differential Cellular Internalization of Anti-CD19 and -CD22
Immunotoxins Results in Different Cytotoxic Activity. Cancer Res.
68, 6300−6305.
(19) Pirie, C. M., Hackel, B. J., Rosenblum, M. G., and Wittrup, K.
D. (2011) Convergent potency of internalized gelonin immunotoxins
across varied cell lines, antigens, and targeting moieties. J. Biol. Chem.
286, 4165−72.
(20) Polito, L., Mercatelli, D., Bortolotti, M., Maiello, S., Djemil, A.,
Battelli, M., and Bolognesi, A. (2017) Two Saporin-Containing
Immunotoxins Specific for CD20 and CD22 Show Different Behavior
in Killing Lymphoma Cells. Toxins 9, 182.
(21) Donaghy, H. (2016) Effects of antibody, drug and linker on the
preclinical and clinical toxicities of antibody-drug conjugates. MAbs 8,
659−671.
ACS Chemical Biology Articles
DOI: 10.1021/acschembio.8b00720
ACS Chem. Biol. 2018, 13, 3153−3160
3159
(22) Srinivasarao, M., and Low, P. S. (2017) Ligand-Targeted Drug
Delivery. Chem. Rev. 117, 12133−12164.
(23) Grawunder, U., and Barth, S. (2017) Next Generation Antibody
Drug Conjugates (ADCs) and Immunotoxins; Springer: Cham,
Switzerland.
(24) Al-Yahyaee, S. A. S., and Ellar, D. J. (1996) Cell targeting of a
pore-forming toxin, CytA δ-endotoxin from Bacillus thuringiensis
subspecies israelensis, by conjugating CytA with anti-Thy 1
monoclonal antibodies and insulin. Bioconjugate Chem. 7, 451−460.
(25) Tejuca, M., Anderluh, G., and Dalla Serra, M. (2009) Sea
anemone cytolysins as toxic components of immunotoxins. Toxicon
54, 1206−1214.
(26) Wan, L., Zeng, L., Chen, L., Huang, Q., Li, S., Lu, Y., Li, Y.,
Cheng, J., and Lu, X. (2006) Expression, purification, and refolding of
a novel immunotoxin containing humanized single-chain fragment
variable antibody against CTLA4 and the N-terminal fragment of
human perforin. Protein Expression Purif. 48, 307−313.
(27) Avila, A. D., de Acosta, C. M., and Lage, A. (1988) A new
immunotoxin built by linking a hemolytic toxin to a monoclonal
antibody specific for immature T lymphocytes. Int. J. Cancer 42, 568−
571.
(28) Avila, A. D., Mateo Acosta, C. De, and Lage, A. (1989) A
carcinoembryonic antigen-directed immunotoxin built by linking a
monoclonal antibody to a hemolytic toxin. Int. J. Cancer 43, 926−929.
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